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We evaluated the potential cardiovascular risk protection of bilirubin in hemodialysis (HD) patients. An enlarged set of studies were
evaluated in 191 HD patients, including hematological study, lipid profile, iron metabolism, nutritional, inflammatory markers,
and dialysis adequacy. The TA duplication screening in the UDP-glucuronosyltransferase 1 A1 (UGT1A1) promoter region was
also performed. The UGT1A1 genotype frequencies in HD patients were 49.2%, 42.4%, and 8.4% for 6/6, 6/7, and 7/7 genotypes,
respectively. Although no difference was found inUGT1A1 genotype distribution between the three tertiles of bilirubin, significant
differences were foundwith increasing bilirubin levels, namely, a decrease in platelet, leukocyte, and lymphocyte counts, transferrin,
oxidized low-density lipoprotein (ox-LDL), ox-LDL/low-density lipoprotein cholesterol ratio, apolipoprotein (Apo) A, Apo B, and
interleukin-6 serum levels and a significant increased concentration of hemoglobin, hematocrit, erythrocyte count, iron, transferrin
saturation, Apo A/Apo B ratio, adiponectin, and paraoxonase 1 serum levels. After adjustment for age these results remained
significant. Our data suggest that higher bilirubin levels are associated with beneficial effects in HD patients, by improving lipid
profile and reducing the inflammatory grade, whichmight contribute to increase in iron availability.These results suggest a potential
cardiovascular risk protection of bilirubin in HD patients.
1. Introduction
Despite the technological advances in hemodialysis (HD)
procedures and medical support in the last years, the mortal-
ity and morbidity of end-stage renal disease (ESRD) patients
under HD remain 10 to 20 times higher than those observed
in the general population [1–3]. Cardiovascular disease
(CVD) events are the main cause of death in these patients
[2]. The prevalence of the classic cardiovascular risk fac-
tors, namely, hypertension, diabetes mellitus, dyslipidemia,
smoking habits, and advanced age per se, cannot explain
the cardiovascular mortality rate. The enhanced inflam-
matory response and oxidative stress usually observed in
HD patients or even other unknown factors may, therefore,
play an important role in the cardiovascular morbidity and
mortality rate in ESRD patients under HD [4].
In 1987, bilirubin was proposed as a potential physiologi-
cal antioxidant and anti-inflammatory agent by Stocker et al.;
they showed that bilirubin, at physiological concentrations,
protects cell membrane fatty acids from oxidation by peroxyl
radicals [5]. It has been shown that both the unconjugated
and conjugated forms of bilirubin can protect low-density
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lipoprotein cholesterol (LDL-c) and other lipids from oxi-
dation by reactive oxygen species [6–8], leading to reduced
baseline levels of oxidized LDL, especially in individuals with
higher bilirubin levels [9]. Several other in vitro and in vivo
studies [5, 10–14] showed bilirubin as an antioxidant and,
therefore, as an important factor in tissue protection against
oxidative and inflammatory damage [12, 15, 16].
Bilirubin is a water-insoluble compound that requires
glucuronidation by a microsomal enzyme, the uridine
diphosphate glucuronosyltransferase-1 A1 (UGT1A1), to be
excreted. The UGT1A1 locus has been mapped to chromo-
some 2q37 [17] and one of the most common genetic variants
that affects the glucuronidation of bilirubin in Caucasians is a
TA duplication polymorphism in the TATA box region of the
promoter.Homozygous individuals carrying theA(TA)7TAA
allele (c.-41 -40dupTA or [TA]7) have higher levels of uncon-
jugated bilirubin, caused by a reduction of 30% in theUGT1A1
transcription [17]. There are few studies on the effect of
bilirubin levels and/or of UGT1A1 gene polymorphism in
the outcome of CVD in the general population, namely,
in the development of coronary artery disease, coronary
heart disease, peripheral vascular disease, and stroke. Recent
epidemiological evidences showed a reduced incidence of
lung disease and all-cause mortality in individuals with high
serum bilirubin levels and with Gilbert’s syndrome [18–
20]. Moreover, a study evaluating the impact of bilirubin
levels and of UGT1A1 polymorphisms on CVD risk and
mortality in ESRD under HD [21] showed that HD patients
with lower serum bilirubin levels presented a more adverse
outcome and, therefore, that the 7/7 genotype might have
an important effect on preventing CVD events and death.
Nevertheless, the mechanisms underlying this protective
effect of bilirubin, in the general population and in ESRD
patients, still remain obscure. Multiple mechanisms could
explain the protective effect of bilirubin, including antioxi-
dant and anti-inflammatory pathways, which may be related
to the powerful redox cycle mediated by biliverdin reductase
that may protect against pathological oxidation processes
occurring during cardiovascular disease [22].
In this work, we aimed to evaluate the potential car-
diovascular risk protection of bilirubin in ESRD patients
under HD. For this, clinical and sociodemographic data,
lipid profile, hematological, dialysis adequacy, inflammatory
and iron metabolism markers, and screening for the TA
duplication in the TATA box of the UGT1A1 promoter were
studied in an ESRD Portuguese sample.
2. Material and Methods
2.1. Subjects. This transversal study included 191 ESRD Por-
tuguese patients under HD (105 males and 86 females, mean
age: 66.13 years; standard derivation [SD]: 14.02 years). All
participants gave their informed consent to participate in this
study that was previously approved by the Ethics Committee
of Fresenius Medical Care, Portugal.
Patients with malignancy, autoimmune disease, and
inflammatory or infectious diseases and with increased levels
of alanina transaminase and/or aspartate transaminase were
excluded. Patients were under therapeutic HD three times
per week, 3–5 hours each session, for a median time of
2.13 (0.82–5.24) years, with a dose of darbepoetin-𝛼 of
0.4 (0.2–0.7)𝜇g/kg/week. For the HD procedure, high-flux
polysulfone FX-class dialyzer of Fresenius (Bad Hamburg,
Germany) was used. The main causes of renal failure in our
patients were diabetic nephropathy (𝑛 = 69), hypertensive
nephrosclerosis (𝑛 = 22), nephritic syndrome (𝑛 = 10), pol-
ycystic kidney disease (𝑛 = 8), obstructive diseases (𝑛 = 7),
hereditary nephropathy (𝑛 = 3), chronic interstitial nephritis
(𝑛 = 2), benign prostate hypertrophy (𝑛 = 1), other diseases
(𝑛 = 8), and uncertain etiology (𝑛 = 61). The Kt/V urea was
calculated using standard formula that takes into considera-
tion the postdialysis serum urea nitrogen concentration and
compares this with the initial or predialysis level.
Blood was collected immediately before the HD proce-
dure, on the second dialysis session of the week, into tubes
containing ethylenediaminetetraacetic acid (EDTA) and into
tubes without anticoagulant, in order to obtain whole blood,
serum, and plasma. Blood samples were processed within
2 hours of collection. Aliquots of plasma, serum, and buffy
coat were immediately stored at −80∘C until the assays were
performed.
2.2. Hematologic and Biochemical Assays. Platelet, leukocyte,
and erythrocyte counts and hematocrit and hemoglobin
concentration were measured by using an automatic blood
cell counter (Sysmex K1000; Sysmex, Hamburg, Germany).
Differential leukocyte counts were evaluated in Wright-
stained blood smears. Reticulocyte count was made by
microscopic counting on blood smears after vital staining
with newmethylene blue (reticulocyte stain; Sigma, St. Louis,
MO, USA). The reticulocyte production index (RPI) was
calculated as an appropriate way to measure the effective
erythrocyte production, by correcting for both changes in
hematocrit (degree of anemia) and for premature reticulocyte
release from the bone marrow [22]. Total bilirubin (TB)
was evaluated using a commercially available kit (diazotized
sulfanilic acid reaction, Roche Diagnostic).
Serum iron concentration was determined using a col-
orimetric method (Iron, Randox Laboratories Ltd., North
Ireland, UK), whereas serum ferritin and transferrin were
measured by immunoturbidimetry (Ferritin, Laboratories
Ltd., North Ireland,UK; Transferrin, Laboratories Ltd., North
Ireland, UK). Transferrin saturation (TS) was calculated by
the formula: TS(%) = 70.9 × serum iron concentration in
𝜇g/dL/serum transferrin concentration in mg/dL. Enzyme-
linked immunosorbent assays were used to measure serum
soluble transferrin receptor (sTfR; human sTfR immunoas-
say, R&D Systems, Minneapolis, MN, USA). Plasma levels
of hepcidin-25 were quantified using a peptide enzyme
immunoassay (Bachem Group, Peninsula Laboratories, LLC,
San Carlos, California).
The lipid profilewas performed in an autoanalyzer (Cobas
Mira S, Roche, Basel, Switzerland), using commercially avail-
able kits; total cholesterol and triglycerides concentrations
were determined by enzymatic colorimetric tests (cholesterol
oxidase-phenol aminophenazone and glycerol-3-phosphate
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oxidase-phenol aminophenazone methods, Roche, resp.);
high-density lipoprotein cholesterol (HDL-c) and LDL-c
were measured using enzymatic colorimetric tests, after
selective separation of HDLc and LDLc fractions (direct
HDL cholesterol and direct LDL cholesterol, Roche, resp.);
oxidized LDL (Ox-LDL) was measured directly in plasma by
using a two-site enzyme immunoassay (oxidized LDL ELISA,
Mercodia, Uppsala, Sweden); serum levels of apolipoprotein
A-I (Apo A-I) and Apo B were evaluated by immunotur-
bidimetric assays (unikit apolipoprotein A-I and B specific
antiserums, Roche); serum lipoprotein(a) [Lp(a)] was quanti-
fied by using an immunoturbidimetric method (Lp(a) Roche
Diagnostics).
Serum C-reactive protein (CRP) was determined by
nephelometry [CRP (latex) high-sensitivity, Roche Diag-
nostics] and serum interleukin-6 (IL-6) was evaluated by
enzyme immunoassays (human IL-6 high-sensitivity ELISA,
eBioscience, Vienna, Austria). Serum albumin levels were
measured using a colorimetric assay end-point method
(albumin plus; Roche GmbH,Mannheim, Germany). Plasma
levels of adiponectinwere evaluated by using a standard com-
mercial enzyme-linked immunoassay (Bender MedSystems,
San Diego, CA, USA).
The activity of paraoxonase 1 (PON1) was assessed
spectrophotometrically and expressed in nmol of p-nitro-
phenol/mL/min. Briefly, paraoxonase activity was measured
by adding serum to 1mL Tris/HCl buffer (100mmol/L, pH
8.0) containing 2mmol/L CaCl
2
and 5.5mmol/L paraoxon
(O,O-diethyl-O-p-nitrophenylphosphate; Sigma Chemical
Co.).The rate of generation of p-nitrophenol was determined
by reading the absorbance at 412 nm, at 37∘C, with the use of
a continuously recording spectrophotometer (Beckman DU-
68).
2.3. DNA Analysis. Genomic DNA was extracted from white
blood cells (buffy coat) by proteinase K/salt precipitation
method. Genotyping TA duplication in the TATA box of
the UGT1A1 promoter was performed by polymerase chain
reaction (PCR). Amplification reaction was carried out in
a thermocycler (MiniOpticon Real-Time PCR Detection
System; Biorad) using 2 𝜇L of DNA, 0.5 𝜇L of each primer at
a concentration of 10 pmol (forward: 5󸀠-TAACTTGGTGTA-
TCGATTGGTTTTTG-3󸀠; reverse: 5󸀠-ACAGCCATGGCG-
CCTTTGCT-3󸀠) and 7.5 𝜇L of PCR Master Mix Promega
(M750B) and water for a final volume of 15𝜇L. The first step
of PCR was 95∘C denaturation for 5 minutes, followed by
35 cycles: denaturation at 95∘C for 30 seconds, annealing
at 55∘C for 30 seconds, extension at 72∘C for 45 seconds,
and final extension at 72∘C for 10 minutes. PCR was fol-
lowed by electrophoresis in 15% polyacrylamide gel in a
Tris/borate/EDTA buffer; the gel was stained with silver
nitrate and photographed.
2.4. Statistical Analysis. Statistical analysis was performed
using the Statistical Package for Social Sciences (SPSS, version
21.0) for Windows (SPSS Inc., Armonk, NY, USA). The
normal distribution of continuous variables was analyzed
using the Kolmogorov-Smirnov test. Continuous variables
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Figure 1: Total bilirubin levels in ESRD patients under HD accord-
ing to the number of TA repeats in the promoter region of UGT1A1.
without normal distribution were log transformed. ANOVA,
supplemented with Tukey’s HSD post hoc test, was conducted
in order to evaluate the effect of tertiles of bilirubin on
continuous covariates. ANCOVA analysis was performed for
age adjustment. The association between tertiles of bilirubin
and categorical variables was analyzed using the Chi-squared
test or Fisher’s exact test. Pearson’s rank correlation coefficient
was used to evaluate relationships between sets of data. The
significance level (𝛼) was set at 0.05.
3. Results
The results were analyzed by two ways, according to the
UGT1A1 genotype, in order to evaluate the changes associated
with a decreasing UGT1A1 activity, and in accordance with
bilirubin levels. For the second analysis, we used the tertiles
of TB as follows: TB < 0.21mg/dL (T1), TB 0.21–0.3mg/dL
(T2), and TB > 0.3mg/dL (T3).
The UGT1A1 genotype frequencies in our HD patients
were 49.2%, 42.4%, and 8.4% for 6/6, 6/7, and 7/7 genotypes,
respectively. When we stratified the results according to
the UGT1A1 genotype, we found that HD patients with the
7/7 genotype presented significantly higher TB levels than
patients with 6/6 genotype and that patients with the 6/7
genotype showed significantly higher TB levels than patients
with 6/6 genotype (Figure 1). The HD patients with the 7/7
genotype presented also a significant increase in HDL-c (6/6
genotype: 38.5 ± 13.4mg/dL; 6/7 genotype: 37.0 ± 12.4mg/dL;
7/7 genotype: 52.7± 17.0mg/dL;𝑃 < 0.05, 7/7 genotype versus
6/6 and 6/7 genotypes). Beyond the increase in HDL-c and
bilirubin in HD patients with 7/7 genotype, no additional
significant differences were observed for the other studied
variables.
When performing multiple comparisons between the
bilirubin tertile groups (Table 1), we observed lower values of
platelets, white blood cells, and lymphocytes in HD patients
in the third tertile group. Concerning the iron metabolism,
this third tertile group showed increasing values in iron and
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Table 1: Results of studied variables (sociodemographic data and dialysis adequacy,UGT1A1 genotype, hematological data, iron metabolism,
lipid profile, and inflammatory markers) by tertiles of bilirubin.
All patients
(𝑛 = 191)
Tertiles of total bilirubin
T1
TB: <0.21mg/dL
(𝑛 = 67)
T2
TB: 0.21 to
0.3mg/dL
(𝑛 = 61)
T3
TB: >0.3mg/dL
(𝑛 = 63)
𝑃 valueb 𝑃 valuec
Sociodemographic data and dialysis adequacy
Age, years 66.1 ± 14.0 67.7 ± 13.6 65.5 ± 15.5 65.1 ± 13.0 0.511 —
Gender (male), 𝑛 (%) 105 (55) 33 (49.3) 31 (50.8) 41 (65.1) 0.142 —
Kt/V urea 1.5 ± 0.3 1.5 ± 0.4 1.5 ± 0.2 1.4 ± 0.2 0.360 0.362
Creatinine, mg/dL 8.1 ± 2.8 7.7 ± 2.4 8.2 ± 2.6 8.5 ± 3.3 0.306 0.407
Urea reduction ratio, % 76.0 ± 6.6 76.2 ± 7.6 76.8 ± 6.2 75.1 ± 5.6 0.377 0.382
Dose of darbepoetin-𝛼, 𝜇g/kg/week 0.4 (0.2–0.7) 0.5 (0.3–0.8) 0.4 (0.2–0.6) 0.5 (0.2–0.9) 0.311 0.335
Central venous catheter use, 𝑛 (%) 44 (23.0) 20 (29.9) 14 (23.0) 10 (15.9) 0.167 —
BMI, kg/m2 25.9 ± 4.6 26.3 ± 5.4 26.1 ± 4.1 25.3 ± 4.2 0.370 0.421
UGT1A1 genotype
6/6, 𝑛 (%) 94 (49.2) 33 (49.3) 35 (57.4) 26 (41.3)
0.236 —6/7, 𝑛 (%) 81 (42.4) 31 (46.3) 20 (32.8) 30 (47.6)
7/7, 𝑛 (%) 16 (8.4) 3 (4.5) 6 (9.8) 7 (11.1)
Hematological data
Hemoglobin, g/dL 11.7 ± 1.4 11.4 ± 1.5 12.0 ± 1.4a 11.8 ± 1.3 0.042 0.041
Hematocrit, % 36.4 ± 4.6 35.3 ± 4.5 37.5 ± 4.7a 36.6 ± 4.3 0.026 0.022
Erythrocytes, ×1012/L 3.8 ± 0.5 3.7 ± 0.5 4.0 ± 0.5a 3.8 ± 0.5 0.043 0.042
Reticulocytes, ×109/L 49.3 (27.4–72.8) 56.0 (28.5–75.6) 40.1 (28.3–66.8) 50.8 (26.2–74.7) 0.318 0.325
RPI 0.9 (0.5–1.4) 0.9 (0.5–1.3) 0.8 (0.5–1.4) 1.1 (0.5–1.5) 0.834 0.830
Platelets, ×109/L 183.7 ± 55.1 197.7 ± 59.9 175.8 ± 43.6 164.0 ± 53.6a 0.027 0.040
White blood cells, ×109/L 6.4 ± 2.0 6.9 ± 2.0 6.3 ± 2.0 6.0 ± 1.9a 0.046 0.057
Neutrophils, ×109/L 4.0 ± 1.5 4.2 ± 1.3 3.8 ± 1.6 3.8 ± 1.6 0.247 0.287
Lymphocytes, ×109/L 1.7 ± 0.7 1.8 ± 0.9 1.7 ± 0.6 1.5 ± 0.5a 0.011 0.011
Neutrophil/lymphocyte ratio 2.3 (1.8–3.3) 2.3 (1.8–3.4) 2.2 (1.5–3.0) 2.5 (2.0–3.3) 0.119 0.120
Iron metabolism
Iron, mg/dL 38.0 (30.0–54.0) 36.0 (29.0–43.0) 41.0 (29.0–55.0) 44.0 (32.0–56.0)a 0.005 0.006
Transferrin, mg/dL 184.3 ± 35.6 193.3 ± 34.6 182.4 ± 39.4 176.4 ± 31.1a 0.023 0.024
Transferrin saturation, % 17.7 ± 10.8 13.9 ± 6.2 17.7 ± 9.4 21.5 ± 14.1a <0.001 <0.001
sTfR, nmol/L 23.3 ± 11.9 21.7 ± 9.4 25.0 ± 14.2 23.4 ± 11.7 0.281 0.284
Ferritin, ng/mL 402.0 ± 152.6 369.3 ± 153.9 419.4 ± 162.7 419.8 ± 137.0 0.093 0.090
Hepcidin-25, ng/mL 1599.1(863.6–2409.0)
1738.0
(1144.3–2637.7)
1649.8
(931.7–2440.1)
1476.6
(537.8–2350.0) 0.108 0.101
Lipid profile
Total cholesterol, mg/dL 154.4 ± 43.4 156.7 ± 34.6 151.3 ± 35.1 155.0 ± 57.3 0.777 0.796
Triglyceride, mg/dL 119.0(91.0–176.0)
135.0
(91.0–183.0)
113.0
(96.5–172.5)
109.0
(85.0–151.0) 0.156 0.103
HDL-cholesterol, mg/dL 42.3 ± 13.5 41.7 ± 12.1 42.5 ± 13.6 42.7 ± 14.9 0.908 0.888
LDL-cholesterol, mg/dL 73.5 ± 29.5 73.8 ± 28.5 73.2 ± 28.0 73.4 ± 32.2 0.992 0.999
ox-LDL, U/L 36.0 ± 15.4 39.8 ± 21.3 34.5 ± 8.6 33.2 ± 12.0a 0.033 0.041
ox-LDL/LDL-c ratio, U/mg 0.053 ± 0.019 0.058 ± 0.025 0.051 ± 0.013a 0.048 ± 0.013a 0.007 0.005
Lp(a), mg/dL 45.4 (25.2–88.1) 50.4 (27.3–106.2) 45.4 (24.1–89.1) 37.4 (24.7–68.2)a 0.052 0.071
Apo A, mg/dL 123.1 ± 30.5 128.9 ± 32.4 125.7 ± 32.7 114.3 ± 23.8a 0.017 0.013
Apo B, mg/dL 72.8 ± 21.8 81.8 ± 21.3 70.6 ± 18.9a 65.4 ± 31.9a <0.001 <0.001
Apo A/Apo B ratio 1.83 ± 0.67 1.68 ± 0.54 1.89 ± 0.74 1.85 ± 0.65a 0.048 0.054
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Table 1: Continued.
All patients
(𝑛 = 191)
Tertiles of total bilirubin
T1
TB: <0.21mg/dL
(𝑛 = 67)
T2
TB: 0.21 to
0.3mg/dL
(𝑛 = 61)
T3
TB: >0.3mg/dL
(𝑛 = 63)
𝑃 valueb 𝑃 valuec
Inflammatory markers
Adiponectin, mg/L 9.2 ± 4.7 7.9 ± 3.7 9.1 ± 4.6 10.7 ± 5.4a 0.003 0.004
PON1, nmol p nitrofenol/mL/min 398.3 ± 92.6 376.0 ± 70.1 398.5 ± 92.9 418.6 ± 106.2a 0.040 0.033
CRP, mg/dL 5.2 (2.3–13.3) 7.1 (3.2–14.6) 4.9 (2.1–13.5) 3.6 (1.9–12.7) 0.393 0.453
IL-6, pg/mL 2.3 (1.4–4.3) 3.1 (2.1–5.4) 2.1 (1.4–4.0)a 1.6 (1.1–3.4)a 0.001 0.003
Albumin, g/dL 3.9 ± 0.4 3.9 ± 0.3 3.9 ± 0.4 3.9 ± 0.4 0.936 0.976
a
𝑃 value < 0.05 for post hoc test considering T1 as reference category; bANOVA analysis for continuous covariates and Chi-squared test or Fisher’s exact test
for categorical covariates. cAdjusting for age (ANCOVA). BMI: body mass index; RPI: reticulocyte production index; sTfR: soluble transferrin receptor; HDL:
high-density lipoprotein; LDL: low-density lipoprotein; ox-LDL: oxidized low-density lipoprotein; Lp(a): lipoprotein (a); Apo A: apolipoprotein A; Apo B:
apolipoprotein B; PON1: paraoxonase 1; CRP: C-reactive protein; IL-6: interleukin-6.
transferrin saturation and decreasing values in transferrin.
In the lipid profile, lower values were found for ox-LDL,
ox-LDL/LDLc ratio, Lp(a), Apo A, and Apo B and higher
values for Apo A/Apo B ratio in the third tertile compared
to the first and second tertiles groups. Increasing values of
adiponectin and PON1 were also observed in the third tertile
group. Post hoc analysis showed that HD patients in the
second tertile of bilirubin, as compared with those in the
first tertile, presented a significant increase in hemoglobin
concentration, hematocrit, and erythrocyte count; a signifi-
cant decrease was also observed for ox-LDL/LDLc ratio, Apo
B, and IL-6. Comparing HD patients in the third tertile of
bilirubin with those in the first tertile, we found a significant
reduction in platelet, leukocyte, and lymphocyte counts;
iron metabolism presented significant changes, namely, an
increase in serum iron and in transferrin saturation, and a
decrease in transferrin; several significant changes were also
observed in the lipid profile, namely, a significant decrease in
ox-LDL, ox-LDL/LDLc ratio, Apo A, and Apo B and a signif-
icant increase in Apo A/Apo B ratio; for the inflammatory
markers, we found a significant rise in adiponectin and
PON1 and a significant reduction in IL-6 serum levels. After
adjusting for age, the results remained significant (Table 1).
No statistical significant differences were found in UGT1A1
genotype between the three tertiles of TB, although HD
patients homozygous for the (TA)7 allele showed an increase
in bilirubin levels when compared to those with genotypes
6/7 and 6/6. Additionally, applying Pearson’s rank correlation,
we also found statistically significant correlations between TB
and adiponectin (𝑟 = 0.238; 𝑃 = 0.001), transferrin (𝑟 =
−0.213; 𝑃 = 0.003), iron (𝑟 = 0.201; 𝑃 = 0.005), transferrin
saturation (𝑟 = 0.307; 𝑃 < 0.001), ferritin (𝑟 = 0.173;
𝑃 = 0.017), Apo A (𝑟 = −0.249; 𝑃 < 0.001), lymphocytes
(𝑟 = −0.223; 𝑃 = 0.002), and IL-6 (𝑟 = −0.193; 𝑃 = 0.008).
4. Discussion
Bilirubin is a key metabolic product of hemoglobin
catabolism and seems to have a protective effect in oxidative
stress conditions, such as atherosclerosis, coronary heart
disease, inflammatory diseases, cancer, and renal disease
[8, 21, 23, 24]. Plasma bilirubin concentrations higher than
20mg/mL are associated with deleterious effects in fetus and
newborns, by increasing the risk of neurological dysfunction
[25, 26], as a result of its toxic effect on neuronal tissue.
Under physiological conditions, most of the bilirubin is
bound to albumin. Homozygosis for the TA duplication
in the promoter region of UGT1A1 gene, associated with
higher levels of unconjugated bilirubin, is considered as the
main cause of Gilbert syndrome in Caucasian population
[2, 17] and justifies some of the interindividual variations
in bilirubin levels, even in the normal population [27]. The
estimated frequency of this allele is 0.35 in Caucasians,
leading to a homozygous genotype in about 10% of the
population, but the frequency is highly variable in different
ethnicities [28, 29].
By studying a group of ESRD patients under HD and
by using a very broad analytical panel, we were able to
demonstrate that higher bilirubin levels, within the normal
range (<1mg/mL), are associated with higher hemoglobin
concentration, lower platelet and lymphocyte counts, an
increased iron availability, an improvement in the lipid
profile, and a decrease in the inflammatory status.
This transversal study showed a prevalence of 8.8% for
homozygosity of the TA duplication in theUGT1A1 promoter
region, which is in accordance with the prevalence reported
for a healthy Portuguese population [30, 31]. Moreover, we
found a relationship between bilirubin levels and the presence
of the TA duplication in the promoter region of UGT1A1;
actually,HDpatients homozygous for the (TA)7 allele showed
an increase in bilirubin levels, when compared with those
heterozygous, or with normal number of TA repeats. It is
known that bilirubin is removed during the dialysis process
[32], but the UGT1A1 genotype may modify serum bilirubin
levels, even before the next dialysis session, as suggested
by the increase in bilirubin levels observed in HD patients
homozygous for the (TA)7 allele. When we stratified the
results by UGT1A1 genotype, we only found a significant
increase in HDL-c in the group of HD patients homozygous
for the (TA)7 allele. Nevertheless, we did not find significant
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differences in HDL-c when the results were stratified by
tertiles of bilirubin, suggesting that this increase in HDL-c
in HD patients homozygous for the (TA)7 allele is linked to a
decrease in glucuronidation, related to the presence of this
polymorphism, more than with the bilirubin serum levels.
This association between higher bilirubin concentrations and
higher HDL-c was previously described in a large number
of studies [23]. Only one study reported decreasing HDL-c
concentrations with increasing bilirubin [33].
Stratifying results by tertiles of bilirubin, no significant
differences were found in UGT1A1 genotype distribution
between groups, reflecting the low penetrance of the TA
duplication polymorphism. Actually, ESRD patients present-
ing higher bilirubin levels showed also high hemoglobin
concentration and hematocrit and erythrocyte counts, sug-
gesting that the red cell mass and hemoglobin concentration
are associated with interindividual variations of bilirubin, as
previously reported in a healthy population [30, 34] and in
individuals with Gilbert’s syndrome [35]. High bilirubin lev-
elsmay be associated alsowith a decrease in the inflammatory
status [36]. Actually, moderate and elevated unconjugated
bilirubin concentrations have been associated with a reduced
inflammatory status, namely, with lower levels of IL-6 [34,
35].We also detected an inverse association between bilirubin
levels with platelets and lymphocyte counts, suggesting that
bilirubin levels may influence hematopoiesis. Recently, it was
described that mild elevated serum unconjugated bilirubin
levels could delay atherosclerotic plaque progress by prevent-
ing thrombus formation through the prevention of collagen
induced platelet aggregation [37]. The immunomodulatory
effects of unconjugated bilirubin may explain its ability to
restrain inflammation [24].
As previously described, high bilirubin levels are asso-
ciated with low inflammatory grade in nonrenal patients
[38, 39] and in ESRD patients [21]. Indeed, a significant
decrease in IL-6 levels can be observed in the last tertile of
bilirubin. Although we have not found significant differences
in CRP between tertiles of bilirubin, a trend towards lower
values with increasing bilirubin was found. As previously
reported, unconjugated bilirubin is negatively associatedwith
CRP levels [37, 38], which is a widely used biomarker for
inflammation status and CVD risk. As IL-6 is a known
inducer of hepatic CRP production, the reduction of IL-6
with bilirubin levels could explain, at least in part, the trend
towards lower values of CRP concentration in our ESRD
patients. It has been suggested that bilirubin is associatedwith
lower CRP levels via reduction of blood lipid concentrations
and not by direct inhibition of inflammation [40].
The rise in adiponectin found in HD patients presenting
higher bilirubin levels and the significant positive correlation
between bilirubin and adiponectin, described here by the
first time in HD patients, could justify also the decreased
inflammatory markers in HD patients presenting lower
bilirubin levels. In fact, several reports demonstrated the anti-
inflammatory effects for adiponectin [41–43]. In addition,
the predictive value of adiponectin in all-cause mortality in
ESRD patients appears to be critically dependent on serum
magnesium (s-Mg) and calcium levels (sCa) since strong
positive and negative associations of adiponectin with s-Mg
and s-Ca were found, respectively, in ESRD patients, and
these associations were independent of each other and inde-
pendent of body composition, nutritional, and inflammatory
status [44]. These data are consistent with other studies,
which showed a 3% to 10.3% increased risk for all-cause
mortality for each 1 mg/mL increment of adiponectin in
chronic kidney disease and ESRD patients [45]. Moreover,
plasma adiponectin is an independent (inverse) predictor
of cardiovascular events and mortality among HD patients.
Analysis of adiponectin and several metabolic risk factors
have shown that adiponectin has a protective function in
prevention of CVD [46]. More recently, it was reported
that an increase in obesity-related markers of the metabolic
syndrome might be associated with lower adiponectin [47].
The inflammatory stimulus has an important impact in
iron metabolism, by mobilizing iron from erythropoiesis
traffic to storage sites within the reticuloendothelial system,
inhibiting erythroid progenitor proliferation and differen-
tiation [48]. These modifications in iron mobilization lead
to an iron depleted erythropoiesis. In this work, the lower
grade of inflammation found in the third tertile of bilirubin
was associated with an increase in serum iron levels and
transferrin saturation and with a decrease in transferrin
levels. Additionally, a significant positive correlation between
bilirubin and serum iron and transferrin saturation and a
significant negative correlation between bilirubin and trans-
ferrin were found. We also observed a trend (𝑃 = 0.108)
towards a decrease in hepcidin serum levels that follows
the increase in bilirubin levels and the decrease in IL-6
serum levels.The increased iron serum levels were previously
reported in Gilbert’s syndrome patients [40] similar to our
ESRD patients that present higher bilirubin levels. This
improvement in iron metabolism seems to be due to the
decrease in the inflammatory status that favors ironmobiliza-
tion from macrophages and increases intestinal iron absorp-
tion. Moreover, it has also been hypothesized that bilirubin
could induce a mild hemolytic effect, liberating haem, which
is subsequently degraded to iron, carbon monoxide and,
ultimately, to bilirubin. Carbon monoxide further stimulates
haemoxygenase-1 andproduction/accumulation of bilirubin,
inducing further red blood cell lyses, completing the loop of
anti-inflammatory compound production [40].
An association between TB and an improvement in the
lipid profile has been already described in several studies in
nonrenal patients [49–51]. There are evidences that support
a role for bilirubin in protecting lipids from various oxygen
radical species [52], particularly from lipid peroxidation
induced by copper [8]. Indeed, as bilirubin and copper accu-
mulate in atherosclerotic lesions, bilirubin could delay copper
induced oxidation of lipids; therefore, the susceptibility to
lipid oxidation might be reduced by elevated concentrations
of the endogenous antioxidant bilirubin. This could explain
the negative relationship between circulating bilirubin and
CVD. Moreover, our HD patients presented an association
between high bilirubin levels (third tertile) and a decrease
in ox-LDL, Apo A, and Apo B and an increase in Apo
A/Apo B ratio, in accordance with a previous report [53].
Lipoproteins, particularly LDL-c, are highly susceptible to
oxidation, and it is known that the atherogenic process
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involves an uptake of oxidized LDL by intimal macrophages
leading to accumulation of lipid-rich foam cells [54]. Given
the antioxidant capacity of bilirubin, it is plausible that
bilirubin protects lipids and lipoproteins against oxidation,
protecting, therefore, against atherogenesis [15]. Indeed, we
found in our HD patients a decrease in ox-LDL/LDL ratio,
showing a reduction in LDL oxidation associated with higher
bilirubin levels. Considering the known involvement of
oxidized LDL in the development of atherosclerosis and the
ability of bilirubin to act as a potent lipid chain-breaking
antioxidant under physiological conditions, the rise of plasma
bilirubin concentrations may reduce the atherogenic risk in
HD patients.
We also found an association between higher bilirubin
levels and higher PON1 activity. PON1 presents antioxidant
properties and contributes to control of the development of
oxidative stress at blood level [55, 56]. As referred to, the
oxidation of LDL is a crucial starting step for the athero-
genic process [57]. By preventing oxidative stress, PON1
contributes to protecting LDL from oxidative modifications,
reducing foam cell formation, and inhibiting atherosclerosis
[58]. In line, serum antioxidant activity of PON1 is an impor-
tant factor in cardiovascular diseases, providing protection
from oxidative stress and lipid peroxidation [59]. PON1
concentration has been proposed as a predictive marker
of cardiovascular mortality and all-cause mortality [60].
Reduced serum PON1 activity has been clearly established
in HD patients and could contribute to accelerating the
development of atherosclerosis in these patients [61], as they
are, probably, more susceptible to the harmful effects of
lipid peroxidation than healthy subjects with a normal PON1
activity. An association between PON1 activity after dialysis
with creatinine changes, advanced glycation end products,
and acrolein has been found, suggesting that uremic toxins
could play a mechanistic role in PON1 inactivation [61]. A
reduced PON1 activity in HD patients who are not under
statin therapy is strongly associated with inflammation,
longer time on dialysis, and high recombinant human ery-
thropoietin (rhEPO) doses, suggesting that the reduction in
PON1 activity may worsen the prognosis of these patients
[62]. Treatment with rhEPO seems to reduce the oxidative
stress and to improve PON1 activity in HD patients [63];
patients who are resistant to this therapy present higher
levels of inflammatory and oxidative stressmarkers that could
contribute to the lower PON1 activity [64].
In conclusion, this work shows that higher bilirubin
levels present potential beneficial effects in ESRD patients
under HD, namely, in the prevention and/or development of
CVD, by improving lipid profile and reducing the inflamma-
tory grade, which may increase iron availability. Moreover,
we described for the first time an association between
high bilirubin levels, within the normal range, with higher
adiponectin and PON1 activities.
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